Grand Rounds: Treatment Options for Clozapine‐Resistant Schizophrenia.
Clozapine is considered a gold-standard medication for treatment-resistant schizophrenia, but close to 40-50% of these patients on clozapine may show poor or no response. What treatment options are available for clozapine-resistant schizophrenia population?
We are excited to announce that Dr. Harvinder Singh will be presenting a grand round on this clinically relevant topic at Einstein Healthcare Network:
Treatment Options for Clozapine-Resistant Schizophrenia
- Date: Monday, November 14, 2022
- Time: 12:00 PM to 1:00 PM
- Location: Virtual Conference Room
- Learning Format: Online
- Watch this Lecture Remotely: https://zoom.us/j/93754423599
Learning Objectives:
At the conclusion of this activity, participants should be able to:
- Understanding factors to consider before considering clozapine augmentation in Schizophrenia.
- Understand the role of Clozapine level & adequate trial duration in clozapine-resistant schizophrenia.
- Identify the available augmentation options for clozapine-resistant schizophrenia.
Classification:
Patient Safety/Risk Management
- This activity includes 1 hours of Patient Safety/Risk Management education.
Psychiatry/Psychology
- This activity includes 1 hours of Psychiatry/Psychology education.
Accreditation Statement:
- Einstein Healthcare Network is accredited by the Pennsylvania Medical Society to provide Continuing Medical Education for physicians.
Credit Designation:
- The Einstein Healthcare Network designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Series Disclosures:
- Faculty and all others who have ability to control the content of continuing education activities sponsored by Einstein Healthcare Network are expected to disclose all of their financial relationships with ineligible companies.
- Ineligible companies are those whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
- All relevant financial relationships have been mitigated prior to the activity date. Event
Disclosures: Speakers:
- Harvinder Singh, MD has no relevant financial relationship﴾s﴿ with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients to disclose.
Commercial Support:
- This activity is not commercially supported.
